Immunotherapeutic stress protein-peptide complexes against cancer
AssigneeMount Sinai School of Medicine of the City University of New York
InventorPramod K. Srivastava
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the Hsp70-peptide, Hsp90-peptide and gp96-peptide complexes.
Claims48
A method for treating a mammal having a tumor sensitive to treatment with a mammalian stress protein-peptide complex comprising administering to the mammal a composition comprising:
- (a) an amount of a purified immunogenic mammalian stress protein-peptide complex isolated from a tumor cell sufficient to elicit an immune response against the tumor, wherein the peptide is noncovalently associated with the stress protein;
- and
- (b) a pharmaceutically acceptable carrier.
A method for treating a mammal having a tumor sensitive to treatment with a mammalian stress protein-peptide complex comprising:
- (a) isolating an immunogenic mammalian stress protein-peptide complex from a cell of a tumor, wherein the peptide is noncovalently associated with the stress protein;
- and
- (b) administering a composition comprising an amount of the isolated complex sufficient to elicit an immune response against the tumor, and a pharmaceutically acceptable carrier.
A method for eliciting in a human an immune response against a tumor comprising administering to the human a composition comprising:
- (a) an amount of a purified immunogenic mammalian stress protein-peptide complex isolated from a cell derived from a tumor sufficient to elicit an immune response against the tumor, wherein the peptide is noncovalently associated with the stress protein;
- and
- (b) pharmaceutically acceptable carrier.
A composition comprising:
- (a) a therapeutically effective amount of purified human stress protein-peptide complex isolated from human tumor tissue excised from a human, wherein the peptide is noncovalently associated with the stress protein;
- and
- (b) a pharmaceutically acceptable carrier.
A composition comprising:
- (a) a therapeutically effective amount of purified human stress protein-peptide complex isolated from a human tumor cell, wherein the peptide is noncovalently associated with the stress protein, and wherein the stress protein is an apparently homogenous Hsp90;
- and (b) a pharmaceutically acceptable carrier.
A composition comprising:
- (a) a therapeutically effective amount of purified human stress protein-peptide complex isolated from a human tumor cell, wherein the peptide is noncovalently associated with the stress protein, and wherein the stress protein-peptide complex is a combination of a Hsp70-peptide complex, a Hsp90-peptide complex, and a human gp96-peptide complex;
- and (b) a pharmaceutically acceptable carrier.
An isolated human stress protein-peptide complex isolated from a human tumor cell, wherein the peptide is noncovalently associated with the stress protein, and wherein the stress protein is human gp96.
An isolated human stress protein-peptide complex isolated from a human tumor cell, wherein the peptide is noncovalently associated with the stress protein, and wherein the stress protein is an apparently homogenous Hsp90.
An isolated human stress protein-peptide complex isolated from a human tumor cell, which is a combination of a Hsp70-peptide complex, a Hsp90-peptide complex, and a human gp96-peptide complex;
- and wherein the peptide is noncovalently associated with the stress protein.
A composition comprising:
- (a) a therapeutically effective amount of purified human stress protein-peptide complex isolated from a human tumor cell, wherein the peptide is noncovalently associated with the stress protein, and wherein the stress protein is human gp96;
- and
- (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.